Connective tissue activation. IX. Modification by pharmacologic agents.
Alpha- and beta-adrenergic blocking agents and imipramine inhibit the increased hyaluronate synthesis that may be induced in human synovial cultures by connective tissue activating peptide (CTAP). Considerations of drug concentration requirements, actions of analogues, and time studies all indicate that the adrenergic blockers do not act in this circumstance as conventional blockers of alpha or beta receptor sites. It is suggested that the membrane-stabilizing properties of these agents may be the important determinant for their limited "antiactivation" effect. Ethacrynic acid, a potent and more complete inhibitor of connective tissue activation, appears to act via a different mechanism.
D000526:Alprenolol / Q000494:pharmacology; D002078:Butoxamine / Q000494:pharmacology; D003238:Connective Tissue / Q000187:drug effects* / Q000378:metabolism; D000242:Cyclic AMP / Q000494:pharmacology; D004976:Ethacrynic Acid / Q000494:pharmacology; D006019:Glycolysis; D006801:Humans; D006820:Hyaluronic Acid / Q000096:biosynthesis; D007099:Imipramine / Q000494:pharmacology; D066298:In Vitro Techniques; D007545:Isoproterenol / Q000494:pharmacology; D007773:Lactates / Q000096:biosynthesis; D008012:Lidocaine / Q000494:pharmacology; D010455:Peptides / Q000494:pharmacology*; D010646:Phentolamine / Q000494:pharmacology; D011343:Procaine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D011458:Prostaglandins E / Q000494:pharmacology; D013583:Synovial Membrane / Q000187:drug effects / Q000378:metabolism
D007773:Lactates; D010455:Peptides; D011458:Prostaglandins E; D002078:Butoxamine; D011343:Procaine; D000526:Alprenolol; D006820:Hyaluronic Acid; D008012:Lidocaine; D011433:Propranolol; D000242:Cyclic AMP; D007545:Isoproterenol; D004976:Ethacrynic Acid; D007099:Imipramine; D010646:Phentolamine